{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:04:26Z","timestamp":1793232266368,"version":"4.5.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,10,21]]},"abstract":"\n Importance<\/jats:title>\n Effective and well-tolerated pharmacotherapies for generalized anxiety disorder (GAD), which is one of the most common psychiatric disorders, are needed.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the dose-response relationship of MM120 (lysergide D-tartrate) in adults with moderate to severe GAD.<\/jats:p>\n <\/jats:sec>\n \n Design, Settings, and Participants<\/jats:title>\n This phase 2b, multicenter, randomized, double-blind, placebo-controlled study enrolled 198 adults aged 18 to 74 years with a primary GAD diagnosis who presented with moderate to severe symptoms (defined by a Hamilton Anxiety Rating Scale [HAM-A] score \u226520) and was conducted at 22 outpatient psychiatric research sites in the US from August 2022 to August 2023. The anxiety and depression end point assessments were conducted by independent central raters who were blinded to the trial protocol, treatment allocation, and study visit date. The last date of follow-up was November 27, 2023.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized to receive a single (freebase equivalent) treatment dose with 25 \u00b5g (n\u2009=\u200939), 50 \u00b5g (n\u2009=\u200940), 100 \u00b5g (n\u2009=\u200940), or 200 \u00b5g (n\u2009=\u200940) of MM120 or placebo (n\u2009=\u200939).<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n The primary outcome was a dose-response relationship assessed using the multiple comparison procedure modeling (MCP-Mod) method for change in HAM-A score at 4 weeks (score range, 0-56; higher scores indicate greater severity; \u22647 indicates no or minimal anxiety; 8-14, mild; 15-23, moderate; and \u226524, severe). The minimal clinically important difference was 2.5 points.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of the 198 participants randomized, 194 were included in the full analysis set (mean age, 41.3 [SD, 13.6] years; 56.7% were female; and 3.6% were Asian, 7.7% were Black or African American, and 83.0% were White). The dose-response relationship assessed using the MCP-Mod method for change in HAM-A score at week 4 was statistically significant for the 100-\u00b5g and the 200-\u00b5g dose groups vs placebo (least-squares mean difference, \u22125.0 points [95% CI, \u22129.6 to \u22120.4 points] with 100 \u00b5g of MM120 and \u22126.0 points [95% CI, \u22129.8 to \u22122.0 points] with 200 \u00b5g of MM120) but the 25-\u00b5g and 50-\u00b5g dose groups did not reach significance vs placebo (least-squares mean difference, \u22121.2 points [95% CI, \u22126.0 to 3.5 points] with 25 \u00b5g of MM120 and \u22121.8 points [95% CI, \u22127.6 to 4.0 points] with 50 \u00b5g of MM120). The adverse events were consistent with the expected effects of MM120. The most common adverse events were visual perceptual changes (illusion, pseudo-hallucination, and visual hallucination), which occurred in 46.2% of participants who received 25 \u00b5g of MM120, in 75.0% who received 50 \u00b5g, in 92.5% who received 100 \u00b5g, in 100% who received 200 \u00b5g, and in 10.3% who received placebo; nausea occurred in 7.7%, 27.5%, 40.0%, 60.0%, and 7.7%, respectively; and headache occurred in 12.8%, 22.5%, 35.0%, 27.5%, and 23.1%.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In participants with moderate to severe GAD, a single dose of MM120 produced a dose-dependent reduction in anxiety. These results support the dose-dependent efficacy of MM120 and inform the dose selection for phase 3 pivotal trials.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05407064<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2025.13481","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T15:31:14Z","timestamp":1756999874000},"page":"1358","source":"Crossref","is-referenced-by-count":46,"title":["Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder"],"prefix":"10.1001","volume":"334","author":[{"given":"Reid","family":"Robison","sequence":"first","affiliation":[{"name":"Cedar Clinical Research, Draper, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Barrow","sequence":"additional","affiliation":[{"name":"Mind Medicine (MindMed) Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Conant","sequence":"additional","affiliation":[{"name":"Mind Medicine (MindMed) Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Foster","sequence":"additional","affiliation":[{"name":"2b Analytics LLC, Wallingford, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie M.","family":"Freedman","sequence":"additional","affiliation":[{"name":"Mind Medicine (MindMed) Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula L.","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Mind Medicine (MindMed) Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamileh","family":"Jemison","sequence":"additional","affiliation":[{"name":"Mind Medicine (MindMed) Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Karas","sequence":"additional","affiliation":[{"name":"Mind Medicine (MindMed) Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Karlin","sequence":"additional","affiliation":[{"name":"Mind Medicine (MindMed) Inc, New York, New York"},{"name":"School of Medicine, Tufts University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Mind Medicine (MindMed) Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miri","family":"Halperin Wernli","sequence":"additional","affiliation":[{"name":"Mind Medicine (MindMed) Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Fava","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"jpc250004r2","doi-asserted-by":"publisher","DOI":"10.1177\/2470547017703993","article-title":"The neurobiological mechanisms of generalized anxiety disorder and chronic stress.","author":"Patriquin","journal-title":"Chronic Stress (Thousand Oaks)"},{"issue":"8","key":"jpc250004r3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.janxdis.2009.07.011","article-title":"Quality of life impairment in generalized anxiety disorder, social phobia, and panic disorder.","volume":"23","author":"Barrera","year":"2009","journal-title":"J Anxiety Disord"},{"key":"jpc250004r4","doi-asserted-by":"publisher","first-page":"887","DOI":"10.2147\/JMDH.S280200","article-title":"Economic and humanistic burden associated with depression and anxiety among adults with non-communicable chronic diseases (NCCDs) in the United States.","volume":"14","author":"Armbrecht","year":"2021","journal-title":"J Multidiscip Healthc"},{"key":"jpc250004r5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1146\/annurev-clinpsy-050212-185544","article-title":"Worry and generalized anxiety disorder: a review and theoretical synthesis of evidence on nature, etiology, mechanisms, and treatment.","volume":"9","author":"Newman","year":"2013","journal-title":"Annu Rev Clin Psychol"},{"issue":"2","key":"jpc250004r6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1176\/appi.focus.19203","article-title":"Pharmacotherapy of anxiety disorders: current and emerging treatment options.","volume":"19","author":"Garakani","year":"2021","journal-title":"Focus (Am Psychiatr Publ)"},{"issue":"6","key":"jpc250004r7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.9740\/mhc.2020.11.326","article-title":"Management of treatment-resistant generalized anxiety disorder.","volume":"10","author":"Ansara","year":"2020","journal-title":"Ment Health Clin"},{"issue":"11","key":"jpc250004r8","doi-asserted-by":"publisher","first-page":"772","DOI":"10.7326\/0003-4819-155-11-201112060-00009","article-title":"Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis.","volume":"155","author":"Gartlehner","year":"2011","journal-title":"Ann Intern Med"},{"issue":"10","key":"jpc250004r9","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/14656566.2018.1491966","article-title":"Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review.","volume":"19","author":"Strawn","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"jpc250004r10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/16506073.2018.1560358","article-title":"Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials.","volume":"49","author":"Carl","year":"2020","journal-title":"Cogn Behav Ther"},{"issue":"21","key":"jpc250004r12","doi-asserted-by":"publisher","first-page":"7322","DOI":"10.3390\/molecules27217322","article-title":"Methods of lysergic acid synthesis\u2014the key ergot alkaloid.","volume":"27","author":"Jastrzebski","year":"2022","journal-title":"Molecules"},{"issue":"4","key":"jpc250004r13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The pharmacology of lysergic acid diethylamide: a review.","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci Ther"},{"issue":"11","key":"jpc250004r14","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/npp.2017.86","article-title":"Modern clinical research on LSD.","volume":"42","author":"Liechti","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"jpc250004r15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11920-022-01363-y","article-title":"The emerging field of psychedelic psychotherapy.","volume":"24","author":"Barber","year":"2022","journal-title":"Curr Psychiatry Rep"},{"issue":"3","key":"jpc250004r16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethyamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study.","volume":"93","author":"Holze","year":"2023","journal-title":"Biol Psychiatry"},{"issue":"9","key":"jpc250004r17","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial.","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"issue":"18","key":"jpc250004r18","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression.","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"jpc250004r19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.","volume":"202","author":"Gasser","year":"2014","journal-title":"J Nerv Ment Dis"},{"issue":"3","key":"jpc250004r20","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1192\/bjp.2024.99","article-title":"LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up.","volume":"225","author":"Holze","year":"2024","journal-title":"Br J Psychiatry"},{"issue":"6","key":"jpc250004r21","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s00213-021-05978-6","article-title":"Safety pharmacology of acute LSD administration in healthy subjects.","volume":"239","author":"Holze","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"jpc250004r22","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.biopsych.2014.11.015","article-title":"Acute effects of lysergic acid diethylamide in healthy subjects.","volume":"78","author":"Schmid","year":"2015","journal-title":"Biol Psychiatry"},{"issue":"3","key":"jpc250004r23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","article-title":"Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.","volume":"46","author":"Holze","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"jpc250004r24","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/2045125316640440","article-title":"Lysergic acid diethylamide: a drug of \u2018use\u2019?","volume":"6","author":"Das","year":"2016","journal-title":"Ther Adv Psychopharmacol"},{"key":"jpc250004r25","first-page":"73","article-title":"44th Annual Meeting poster abstracts: genetic toxicity testing of MM-120 (lysergide D-tartrate) demonstrates no evidence of mutagenicity #124.","volume":"43","author":"Tripp","year":"2024","journal-title":"Int J Toxicol"},{"issue":"4","key":"jpc250004r26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/mpr.323","article-title":"Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder.","volume":"19","author":"Matza","year":"2010","journal-title":"Int J Methods Psychiatr Res"},{"issue":"4","key":"jpc250004r28","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/da.1033","article-title":"Reliability and validity of a Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A).","volume":"13","author":"Shear","year":"2001","journal-title":"Depress Anxiety"},{"key":"jpc250004r29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change.","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"issue":"2","key":"jpc250004r30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cct.2003.10.016","article-title":"Assessment of blinding in clinical trials.","volume":"25","author":"Bang","year":"2004","journal-title":"Control Clin Trials"},{"issue":"12","key":"jpc250004r32","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia\u2013Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"3","key":"jpc250004r33","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/j.1541-0420.2005.00344.x","article-title":"Combining multiple comparisons and modeling techniques in dose-response studies.","volume":"61","author":"Bretz","year":"2005","journal-title":"Biometrics"},{"issue":"10","key":"jpc250004r34","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/sim.6052","article-title":"Model-based dose finding under model uncertainty using general parametric models.","volume":"33","author":"Pinheiro","year":"2014","journal-title":"Stat Med"},{"issue":"8","key":"jpc250004r35","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1177\/0269881107076996","article-title":"An effect-size analysis of pharmacologic treatments for generalized anxiety disorder.","volume":"21","author":"Hidalgo","year":"2007","journal-title":"J Psychopharmacol"},{"issue":"1","key":"jpc250004r36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ph3010019","article-title":"The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments.","volume":"3","author":"Machado-Vieira","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"jpc250004r37","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","article-title":"Towards an understanding of psychedelic-induced neuroplasticity.","volume":"48","author":"Calder","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"jpc250004r38","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1017\/S1461145710001434","article-title":"Evidence-based pharmacological treatment of generalized anxiety disorder.","volume":"14","author":"Baldwin","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"issue":"9","key":"jpc250004r39","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials.","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1572","key":"jpc250004r40","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1098\/rstb.2010.0394","article-title":"Lessons learned from placebo groups in antidepressant trials.","volume":"366","author":"Mora","year":"2011","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"1","key":"jpc250004r41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2023-300654","article-title":"Blinding successfulness in antipsychotic trials of acute treatment for schizophrenia: a systematic review.","volume":"26","author":"Tajika","year":"2023","journal-title":"BMJ Ment Health"},{"key":"jpc250004r31","author":"Karas","year":"2024"},{"key":"jpc250004r1","unstructured":"Ringeisen? H, Edlund? M, Guyer? H, . Mental and Substance Use Disorders Prevalence Study (MDPS): findings report. Accessed April 4, 2024. https:\/\/www.rti.org\/publication\/mental-and-substance-use-disorders-prevalence-study\/fulltext.pdf"},{"key":"jpc250004r11","unstructured":"FDA approves Cymbalta for treatment of generalized anxiety disorder. News release. Lilly; February 26, 2007. Accessed July 26, 2024. https:\/\/investor.lilly.com\/static-files\/499f0aa3-281f-49f4-9655-049aae179593"},{"key":"jpc250004r27","unstructured":"Hamilton Anxiety Rating Scale (HAM-A). Accessed March 25, 2024. https:\/\/dcf.psychiatry.ufl.edu\/files\/2011\/05\/HAMILTON-ANXIETY.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2838505\/jama_robison_2025_pc_250004_1760999661.70333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:01:27Z","timestamp":1761058887000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2838505"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":41,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,10,21]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.13481","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,21]]}}}